Answers are grounded in this paper and cite their sources.
Small molecule inhibitors of glutaminase (GSL1) are described as potential treatment of metabolic diseases including obesity, diabetes, liver diseases, muscular atrophy and atherosclerosis. Glutaminolysis is an alternative to glycosis as a source of carbon for energy homeostasis and is a major source of energy in the brain and other organs. Glutaminase (GSL1) is a mitochondrial enzyme converting glutamine into glutamate through glutaminolysis. Excessive glutaminolysis is associated with accelerated aging.
No takes yet. Share an insight, caveat, or question.
Gérard Rossé (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: